Case Presentation: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia
John Allan, MD, presents the case of a 70-year-old woman with newly diagnosed chronic lymphocytic leukemia.
EP: 1.Case Presentation: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia
EP: 2.Ongoing Challenges in the Treatment of Frontline Chronic Lymphocytic Leukemia
EP: 3.Frontline Treatment Approaches in Patients with Chronic Lymphocytic Leukemia
EP: 4.Considering Comorbidities when Choosing a Chronic Lymphocytic Leukemia Treatment
EP: 5.Case Review: Recommended Monitoring for Newly Diagnosed Chronic Lymphocytic Leukemia
EP: 6.Strategies for Managing Adverse Events when Treating Chronic Lymphocytic Leukemia
EP: 7.Novel Strategies and Treatments in Chronic Lymphocytic Leukemia
Case: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia
Initial Presentation:
- A 70-year-old woman presented to her PCP for a routine checkup complaining of moderate, progressive fatigue and unintended weight loss over the last 4 months.
- PMH: hypercholesterolemia (well controlled on medication; reports having a relatively healthy diet)
- SH: Retired nurse; exercises at least 30 minutes per day most days of the week; enjoys spending time with her grandkids and traveling with her spouse; ~1-2 drinks in social settings per week
- PE: vital signs WNL, right cervical lymphadenopathy~2.7 cm, spleen palpable 5 cm below costal margin, otherwise well-appearing
- Laboratory findings:
- WBC 186,000; 75% lymphocytes
- Hb 9.4 g/dL
- Platelets 85 X 109/L
- Cr Cl: 61 ml/min
- Flow cytometry; CD5+, CD19+, CD23+
- beta2M, 3.8 mg/L
- IGHV mutational status: unmutated; TP53 unmutated
- ECOG PS 0
- BM biopsy; diffuse infiltration by CLL
Treatment:
- Options for treatment were reviewed and discussed with the patient, her spouse, and the care team.
- The decision was made to initiate the patient on fixed duration venetoclax + obinutuzumab.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
